<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39383403</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-8060</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Memorias do Instituto Oswaldo Cruz</Title><ISOAbbreviation>Mem Inst Oswaldo Cruz</ISOAbbreviation></Journal><ArticleTitle>Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy.</ArticleTitle><Pagination><StartPage>e240093</StartPage><MedlinePgn>e240093</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e240093</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/0074-02760240093</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0074-02762024000100852</ELocationID><Abstract><AbstractText>Tuberculosis (TB) continues to be the world's leading killer of infectious diseases. Despite global efforts to gradually reduce the number of annual deaths and the incidence of this disease, the coronavirus disease 19 (COVID-19) pandemic caused decreased in TB detection and affected the prompt treatment TB which led to a setback to the 2019 rates. However, the development and testing of new TB vaccines has not stopped and now presents the possibility of implanting in the next five years a new vaccine that is affordable and might be used in the various key vulnerable populations affected by TB. Then, this assay aimed to discuss the main vaccines developed against TB that shortly could be selected and used worldwide, and additionally, evidence the Brazilian potential candidates' vaccines in developing in Brazil that could be considered among those in level advanced to TB end.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Junqueira-Kipnis</LastName><ForeName>Ana Paula</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-4200-6617</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Rede Goiana de Pesquisa em Tuberculose, Goiânia, GO, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Luciana Cesar de Cerqueira</ForeName><Initials>LCC</Initials><AffiliationInfo><Affiliation>Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croda</LastName><ForeName>Júlio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universidade Federal do Mato Grosso do Sul, Faculdade de Medicina, Mato Grosso do Sul, MS, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Mato Grosso do Sul, MS, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale School of Public Health, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chimara</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto Adolfo Lutz, Núcleo de Tuberculose e Micobacterioses, São Paulo, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Anna Cristina C</ForeName><Initials>ACC</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcêncio</LastName><ForeName>Ricardo Alexandre</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Universidade de São Paulo, Escola de Enfermagem de Ribeirão Preto, Ribeirão Preto, SP, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rede Brasileira de Pesquisas em Tuberculose - REDE TB, Parque Tecnológico da Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Mem Inst Oswaldo Cruz</MedlineTA><NlmUniqueID>7502619</NlmUniqueID><ISSNLinking>0074-0276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D032581">Tuberculosis Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032581" MajorTopicYN="Y">Tuberculosis Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="N">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. The authors have no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>22</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>15</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39383403</ArticleId><ArticleId IdType="pmc">PMC11452070</ArticleId><ArticleId IdType="doi">10.1590/0074-02760240093</ArticleId><ArticleId IdType="pii">S0074-02762024000100852</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Global tuberculosis report 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023</Citation></Reference><Reference><Citation>da Costa C. C.Onyebujoh P.Thiry G.Zumla A Advances in development of new tuberculosis vaccines. Curr Opin Pulm Med. 2023;29(3):143–148.</Citation><ArticleIdList><ArticleId IdType="pubmed">36866744</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO preferred product characteristics for new tuberculosis vaccine. 2018. https://www.who.int/publications/i/item/WHO-IVB-18.06</Citation></Reference><Reference><Citation>Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis. 2022;22(1):e2–e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">34506734</ArticleId></ArticleIdList></Reference><Reference><Citation>Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV. Efficacy of BCG vaccine in the prevention of tuberculosis Meta-analysis of the published literature. JAMA. 1994;271:698–702.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE. Protection by BCG vaccine against tuberculosis a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–480.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336911</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez L, Cords O, Liu Q, Acuna-Villaorduna C, Bonnet M, Fox GJ. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course a systematic review and individual participant data meta-analysis. Lancet Glob Health. 2022;10:e1307–e1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10406427</ArticleId><ArticleId IdType="pubmed">35961354</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil the BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">16214599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantas OM, Ximenes RA, de Albuquerque MF, da Silva NL, Montarroyos UR, de Souza WV. A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int J Tuberc Lung Dis. 2006;10(5):536–541.</Citation><ArticleIdList><ArticleId IdType="pubmed">16704036</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreto ML, Pilger D, Pereira SM, Genser B, Cruz AA, Cunha SS. Causes of variation in BCG vaccine efficacy examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses. Vaccine. 2014;32(30):3759–3764.</Citation><ArticleIdList><ArticleId IdType="pubmed">24852722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N. Prevention of M tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379:138–149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5937161</ArticleId><ArticleId IdType="pubmed">29996082</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  BCG vaccines: WHO position paper - February 2018. World Health Organization. 2018 https://www.who.int/publications/i/item/who-wer9308-73-96</Citation><ArticleIdList><ArticleId IdType="pubmed">29609965</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children systematic review and meta-analysis. BMJ. 2014;349:g4643–g4643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122754</ArticleId><ArticleId IdType="pubmed">25097193</ArticleId></ArticleIdList></Reference><Reference><Citation>Scriba TJ, Netea MG, Ginsberg AM. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Sem Immunol. 2020;50:101431–101431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7786643</ArticleId><ArticleId IdType="pubmed">33279383</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelzer PT, Smit Y, Tiemersma EW, Huong NT, Nhung NV, Cobelens F. Does BCG vaccination protect against infection with M tuberculosis? Int J Tuberc Lung Dis. 2022;26(6):529–536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165740</ArticleId><ArticleId IdType="pubmed">35650705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancione S, Alvarez JV, Alsdurf H, Pai M, Zwerling AA. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas. BMJ Glob Health. 2022;7(1):e007462</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8764994</ArticleId><ArticleId IdType="pubmed">35039309</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane H. Revaccination with BCG does it work? Lancet Infect Dis. 2024;24(6):559–560.</Citation><ArticleIdList><ArticleId IdType="pubmed">38423022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling AC. The BCG replacement vaccine VPM1002 from drawing board to clinical trial. Expert Rev Vaccines. 2014;13(5):619–630.</Citation><ArticleIdList><ArticleId IdType="pubmed">24702486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B. t al The recombinant Bacille Calmette-Guérin vaccine VPM1002 ready for clinical efficacy testing. Front Immunol. 2017;8:1147–1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610719</ArticleId><ArticleId IdType="pubmed">28974949</ArticleId></ArticleIdList></Reference><Reference><Citation>Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol. 2017;24(2):e00439–e00416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299117</ArticleId><ArticleId IdType="pubmed">27974398</ArticleId></ArticleIdList></Reference><Reference><Citation>Dockrell HM. A next generation BCG vaccine moves forward. Lancet Infect Dis. 2022;22(10):1404–1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">35772448</ArticleId></ArticleIdList></Reference><Reference><Citation>Díaz C. Pérez Del Palacio J.Valero-Guillén PL.Mena García P.Pérez I.Vicente F Comparative metabolomics between Mycobacterium tuberculosis and the MTBVAC vaccine candidate. ACS Infect Dis. 2019;5(8):1317–1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">31099236</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín C, Marinova D, Aguiló N, Gonzalo-Asensio J. MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG. Vaccine. 2021;39(50):7277–7285.</Citation><ArticleIdList><ArticleId IdType="pubmed">34238608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacámara S, Martin C. MTBVAC a tuberculosis vaccine candidate advancing towards clinical efficacy trials in TB prevention. Arch Bronconeumol. 2023;59(12):821–828.</Citation></Reference><Reference><Citation>Dijkman K, Aguilo N, Boot C, Hofman SO, Sombroek CC, Vervenne RAW. Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Rep Med. 2021;2(1):100187–100187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7817873</ArticleId><ArticleId IdType="pubmed">33521701</ArticleId></ArticleIdList></Reference><Reference><Citation>Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein1. J Immunol. 2004;172(12):7618–7628.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187142</ArticleId></ArticleIdList></Reference><Reference><Citation>Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr Opin Immunol. 2012;24(3):310–315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383374</ArticleId><ArticleId IdType="pubmed">22521140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillard P, Yang P-C, Danilovits M, Su W-J, Cheng S-L, Pehme L. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis a phase II randomised study. Tuberculosis. 2016;100:118–127.</Citation><ArticleIdList><ArticleId IdType="pubmed">27553419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumarasamy N, Poongulali S, Bollaerts A, Moris P, Beulah FE, Ayuk LN. A randomized, controlled safety, and immunogenicity trial of the M72/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults. Medicine. 2016;95:e2459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4998253</ArticleId><ArticleId IdType="pubmed">26817879</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacher EG, Cavassini M, Audran R, Thierry A-C, Bollaerts A, Cohen J. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy a phase I/II, randomized trial. AIDS. 2014;28:1769–1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">24911353</ArticleId></ArticleIdList></Reference><Reference><Citation>Tait DR, Hatherill M. van der Meeren O.Ginsberg AM.van Brakel E.Salaun B Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–2439.</Citation><ArticleIdList><ArticleId IdType="pubmed">31661198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson L, Gracie L, Kidy F, Thomas GN, Nirantharakumar K, Greenfield S. Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries a systematic review of randomised controlled clinical trials. BMC Infect Dis. 2023;23(1):120–120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9951834</ArticleId><ArticleId IdType="pubmed">36829123</ArticleId></ArticleIdList></Reference><Reference><Citation>Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants an open-label randomized controlled trial. Tuberculosis. 2014;6:564–578.</Citation><ArticleIdList><ArticleId IdType="pubmed">25305000</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasina DV, Kleymenov DA, Manuylov VA, Mazunina EP, Koptev EY, Tukhovskaya EA. First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate safety and immunogenicity assessment. Vaccines. 2019;7(4):166–166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963980</ArticleId><ArticleId IdType="pubmed">31683812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One. 2017;12(4):e0176784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409163</ArticleId><ArticleId IdType="pubmed">28453555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachuk AP, Bykonia EN, Popova LI, Kleymenov DA, Semashko MA, Chulanov VP, et al. safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712213</ArticleId><ArticleId IdType="pubmed">33153191</ArticleId></ArticleIdList></Reference><Reference><Citation>Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine first-in-human trial. npj. Vaccines. 2018;3:34–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123489</ArticleId><ArticleId IdType="pubmed">30210819</ArticleId></ArticleIdList></Reference><Reference><Citation>Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One. 2011;6(1):e16333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3027669</ArticleId><ArticleId IdType="pubmed">21298114</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin SL, Reese VA, Huang PW, Beebe EA, Podell BK, Reed SG. Protection and long-lived immunity induced by the ID93/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate. Clin Vaccine Immunol. 2015;23(2):137–147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744918</ArticleId><ArticleId IdType="pubmed">26656121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon KW, Lee A, Larsen SE, Baldwin SL, Coler RN, Reed SG. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci Rep. 2019;9:15560–15560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820558</ArticleId><ArticleId IdType="pubmed">31664157</ArticleId></ArticleIdList></Reference><Reference><Citation>Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania a randomized controlled, double-blind phase 2b trial. Vaccine. 2020;38(46):7239–7245.</Citation><ArticleIdList><ArticleId IdType="pubmed">33004239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahey T, Laddy D, Hill K, Schaeffer J, Hogg A, Keeble J. Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PLoS One. 2016;11(12):e0168521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173179</ArticleId><ArticleId IdType="pubmed">27997597</ArticleId></ArticleIdList></Reference><Reference><Citation>von Reyn CF, Lahey T, Arbeit RD, Landry B, Kailani L, Adams LV. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG a randomized, controlled trial of DAR-901. PLoS One. 2017;12(5):e0175215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429024</ArticleId><ArticleId IdType="pubmed">28498853</ArticleId></ArticleIdList></Reference><Reference><Citation>Masonou T, Hokey DA, Lahey T, Halliday A, Berrocal-Almanza LC, Wieland-Alter WF. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults a randomized, placebo-controlled trial. PLoS One. 2019;14(5):e0217091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6532882</ArticleId><ArticleId IdType="pubmed">31120957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogra S, Jain S, Sharma A, Chhabra S, Narang T. Mycobacterium Indicus Pranii (MIP) vaccine pharmacology, indication, dosing schedules, administration, and side effects in clinical practice. Indian Dermatol Online J. 2023;14(6):753–761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10718117</ArticleId><ArticleId IdType="pubmed">38099011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Saqib M, Singh B, Pal L, Nishikanta A, Bhaskar S. Mycobacterium indicus pranii induced memory t-cells in lung airways are sentinels for improved protection against M tb infection. Front Immunol. 2019;10:2359–2359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813244</ArticleId><ArticleId IdType="pubmed">31681272</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun. 1998;66(1):169–175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC107873</ArticleId><ArticleId IdType="pubmed">9423854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima KM, Bonato VL, Faccioli LH, Brandão IT, dos Santos SA, Coelho-Castelo AA. Comparison of different delivery systems of vaccination for the induction of protection against tuberculosis in mice. Vaccine. 2001;19(25-26):3518–3525.</Citation><ArticleIdList><ArticleId IdType="pubmed">11348719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruberti M, De Melo LK, Dos Santos SA, Brandao IT, Soares EG. Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention. J Drug Target. 2004;12(4):195–203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15506168</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CL, Bonato VL, Coelho-Castelo AA, De Souza AO, Santos SA, Lima KM. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther. 2005;12(3):281–287.</Citation><ArticleIdList><ArticleId IdType="pubmed">15526006</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lima MR, Leandro ACCS, de Souza AL, Barradas MM, Roma EH, Fernandes ATG. Safety and immunogenicity of an in vivo muscle electroporation delivery system for DNA-hsp65 tuberculosis vaccine in cynomolgus monkeys. Vaccines. 2023;11(12):1863–1863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10747856</ArticleId><ArticleId IdType="pubmed">38140266</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, Macedo GC. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol. 2006;13(8):930–935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1539111</ArticleId><ArticleId IdType="pubmed">16893994</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castro CP, Souza BM, Mancha-Agresti P, Pereira VB, Zurita-Turk M, Preisser TM. Lactococcus lactis FNBPA+ (pValac e6ag85a) induces cellular and humoral immune responses after oral immunization of mice. Front Microbiol. 2021;12:676172–676172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8173160</ArticleId><ArticleId IdType="pubmed">34093498</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlétti D, da Fonseca DM, Gembre AF, Masson AP, Weijenborg Campos L, Leite LCC. A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice. Clin Vaccine Immunol. 2013;20(8):1162–1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3754502</ArticleId><ArticleId IdType="pubmed">23740922</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzi C, Peiter AC, Oliveira TL, Seixas ACP, Neto, Leal KS, Hartwig DD. Stable expression of Mycobacterium bovis antigen 85B in auxotrophic M bovis bacillus Calmette-Guérin. Mem Inst Oswaldo Cruz. 2017;112(2):123–130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293121</ArticleId><ArticleId IdType="pubmed">28177046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzi C, Bianco MV, Blanco FC, Soria M, Gravisaco MJ, Montenegro V. Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One. 2012;7(12):e51396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519572</ArticleId><ArticleId IdType="pubmed">23251517</ArticleId></ArticleIdList></Reference><Reference><Citation>Araújo-Filho JA, Vasconcelos AC, Jr, Sousa EM, Silveira C, Ribeiro E, Kipnis A. Extensively drug-resistant tuberculosis a case report and literature review. Braz J Infect Dis. 2008;12(5):447–452.</Citation><ArticleIdList><ArticleId IdType="pubmed">19219288</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva BDS, Trentini MM, da Costa AC, Kipnis A, Junqueira-Kipnis AP. Different phenotypes of CD8+ T cells associated with bacterial load in active tuberculosis. Immunol Lett. 2014;160(1):23–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">24694750</ArticleId></ArticleIdList></Reference><Reference><Citation>Limongi LC, Olival L, Conde MB, Junqueira-Kipnis AP. Determination of levels of specific IgA to the HspX recombinant antigen of Mycobacterium tuberculosis for the diagnosis of pleural tuberculosis. J Bras Pneumol. 2011;37(3):302–307.</Citation><ArticleIdList><ArticleId IdType="pubmed">21755184</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagmignan A, Costa ACD, Viana JL, Lima LG, Neto, Monteiro CA, Gaioso AG., Neto Identification of specific antibodies against the Ag85C-MPT51-HspX fusion protein (CMX) for serological screening of tuberculosis in endemic area. Expert Rev Clin Immunol. 2017;13(8):837–843.</Citation><ArticleIdList><ArticleId IdType="pubmed">28633546</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa EM, da Costa AC, Trentini MM. de Araújo Filho JA.Kipnis A.Junqueira-Kipnis AP Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection. PLoS One. 2012;7(10):e47781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485045</ArticleId><ArticleId IdType="pubmed">23133523</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira-Kipnis AP, Souza CC, Carvalho ACO, de Oliveira FM, Almeida VP, de Paula AR. Protease-based subunit vaccine in mice boosts BCG protection against Mycobacterium tuberculosis. Vaccines. 2022;10(2):306–306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877678</ArticleId><ArticleId IdType="pubmed">35214766</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos BPO, Trentini MM, Machado RB, Celes MRN, Kipnis A, Petrovsky N. Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection. Hum Vaccin Immunother. 2017;13(12):2967–2976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718803</ArticleId><ArticleId IdType="pubmed">28937879</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa AC, Costa-Júnior AO, de Oliveira FM, Nogueira SV, Rosa JD, Resende DP. A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. PLoS One. 2014;9(11):e112848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232451</ArticleId><ArticleId IdType="pubmed">25398087</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira FM, Trentini MM, Junqueira-Kipnis AP, Kipnis A. The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects. Mem Inst Oswaldo Cruz. 2016;111(4):223–231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830111</ArticleId><ArticleId IdType="pubmed">27074251</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento IP, Rodriguez D, Santos CC, Amaral EP, Rofatto HK, Junqueira-Kipnis AP. Recombinant BCG expressing LTAK63 adjuvant induces superior protection against Mycobacterium tuberculosis. Sci Rep. 2017;7(1):2109–2109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437048</ArticleId><ArticleId IdType="pubmed">28522873</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos CC, Rodriguez D, Issamu AK, Leite LCC, Nascimento IP. Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria. Hum Vaccin Immunother. 2020;16(3):673–683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227645</ArticleId><ArticleId IdType="pubmed">31665996</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraes L, Trentini MM, Fousteris D, Eto SF, Chudzinski-Tavassi AM, Leite LCC. CRISPR/Cas9 approach to generate an auxotrophic BCG strain for unmarked expression of LTAK63 adjuvant a tuberculosis vaccine candidate. Front Immunol. 2022;13:867195–867195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005855</ArticleId><ArticleId IdType="pubmed">35432328</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques-Neto LM, Trentini MM, Kanno AI, Rodriguez D, Leite LCC. Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice. Front Immunol. 2023;14:1205449–1205449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10374402</ArticleId><ArticleId IdType="pubmed">37520577</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>